This content is machine translated Mantle cell lymphoma First- and second-line lenalidomide Mantle cell lymphoma (MZL) is an aggressive non-Hodgkin’s lymphoma that accounts for approximately 3-6% of all NHL cases. It has a poor prognosis, especially after failure of first-line therapy. Lenalidomide…
